Sanofi

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. 

CEO
Paul Hudson
CEOPaul Hudson
Employees
84,587
Employees84,587
Headquarters
Paris, Ile-de-France
HeadquartersParis, Ile-de-France
Founded
1994
Founded1994
Employees
84,587
Employees84,587

SNY Key Statistics

Market cap
125.22B
Market cap125.22B
Price-Earnings ratio
12.59
Price-Earnings ratio12.59
Dividend yield
3.16%
Dividend yield3.16%
Average volume
2.56M
Average volume2.56M
High today
$50.72
High today$50.72
Low today
$50.07
Low today$50.07
Open price
$50.14
Open price$50.14
Volume
2.10M
Volume2.10M
52 Week high
$60.12
52 Week high$60.12
52 Week low
$44.62
52 Week low$44.62

SNY News

Benzinga 2d
Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease

On Friday, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for Sanofi SA’s (NASDAQ:SNY) Rezurock...

Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease
Benzinga 2d
What's Going On With Sanofi Stock Friday? - Sanofi - Benzinga

...

What's Going On With Sanofi Stock Friday? - Sanofi - Benzinga
Seeking Alpha 2d
Sanofi and Insmed among winners of EU drug recommendations this week

Healthcare Sanofi and Insmed among winners of EU drug recommendations this week Oct. 17, 2025 8:57 AM ET Sanofi (SNY) Stock, INSM Stock, REGN Stock, RHHBY Stock...

Sanofi and Insmed among winners of EU drug recommendations this week

More SNY News

TipRanks 3d
Sanofi’s Rilzabrutinib Trial: A Potential Game-Changer for IgG4-related Disease

Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock p...

TipRanks 4d
Sanofi’s AlphaMedix Achieves Key Efficacy Endpoints in Phase 2 Study

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

TipRanks 5d
Sanofi’s New COPD Treatment Study: A Potential Game-Changer?

Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock p...

Simply Wall St 5d
How Investors Are Reacting To Revvity and Sanofi's Collaboration on Early Type 1 Diabetes Detection

On October 2, 2025, Sanofi announced a collaboration supporting Revvity in expanding its type 1 diabetes (T1D) offering with the development of a new 4-plex in...

How Investors Are Reacting To Revvity and Sanofi's Collaboration on Early Type 1 Diabetes Detection
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.